Clinical trials: Pancreatic Cancer Stage
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.
- Conditions
- Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
- Trial name
- NCT04805307
- Testing
- CMG901
- Where
- 32 sites in China
- Volunteers
- 176 people
- Sponsor
- Keymed Biosciences Co.Ltd
Pancreatic Cancer
Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer
The purpose of this study is to evaluate the safety, tolerability and immune response of different doses of VEGFR2-169 emulsified with Montanide ISA 51 in combination with gemcitabine and to determine the recommended phase II…
- Trial name
- NCT00622622
- Testing
- VEGFR2-169 and gemcitabine
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Wakayama Medical University
Advanced Pancreatic Ductal Adenocarcinoma
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer.
- Trial name
- ATARI-PDAC (NCT07348107)
- Testing
- ATRA, Arsenic Trioxide (ATO), Gemcitabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Daniel Breadner
Gastrointestinal Neoplasms, Pancreatic Neoplasms
A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation using 4-15 MV photons; plus Gemcitabine, NSC-613327.
- Trial name
- NCT00001431
- Testing
- gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CAPAFOUR (NCT04990037)
- Testing
- CAN04, FOLFIRINOX
- Where
- 9 sites in France, Spain
- Volunteers
- 25 people
- Sponsor
- Cantargia AB
Advanced Pancreatic Cancer
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma.
- Trial name
- NCT04643405
- Testing
- APG-1387 for Injection, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Ascentage Pharma Group Inc.
Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
Title: Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer.
- Conditions
- Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- NCT02035072
- Testing
- Gemcitabine, Oxaliplatin, Hypofractionated RT
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Melanoma, Breast Cancer
Safety Study of Modified Vaccinia Virus to Cancer
The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.
- Conditions
- Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer
- Trial name
- NCT00574977
- Testing
- Vaccinia virus (vvDD-CDSR)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- David Bartlett
Pancreatic Cancer
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to…
- Trial name
- NCT02278458
- Testing
- icotinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the…
- Conditions
- Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Trial name
- THREAD (NCT03825289)
- Testing
- Hydroxychloroquine, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Pancreatic Cancer, Unresectable Pancreatic Cancer
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
The purpose of this study is to evaluate the efficacy and safety of stereotactic radiation therapy given in five fractions (30 Gray in 5 fractions) followed by gemcitabine in patients with locally advanced pancreatic cancer.
- Trial name
- NCT01304160
- Testing
- stereotactic body radiotherapy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00095966
- Testing
- sorafenib tosylate, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07261631
- Testing
- 68Ga-NNS309, 177Lu-DFC413
- Where
- 9 sites in United States, Canada and 5 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Advanced Pancreatic Cancer
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
This study will assess the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer
- Trial name
- NCT05580445
- Testing
- CT-707, Toripalimab, Gemcitabine
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Pancreatic Cancer
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation.
- Trial name
- NCT07689539
- Testing
- DN022150, Chemotherapy
- Volunteers
- 360 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390826
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.